Moleculin Biotech (NASDAQ:MBRX) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Moleculin Biotech (NASDAQ:MBRX) in a research report released on Saturday morning. The brokerage issued a sell rating on the stock.

Separately, Maxim Group lowered their price objective on Moleculin Biotech from $20.00 to $8.00 and set a “buy” rating for the company in a research report on Tuesday, November 12th.

Moleculin Biotech Price Performance

Moleculin Biotech stock opened at $1.39 on Friday. Moleculin Biotech has a 1-year low of $1.33 and a 1-year high of $10.35. The business has a fifty day moving average price of $2.00 and a 200-day moving average price of $2.41.

About Moleculin Biotech

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.